Giant-cell tumor of bone: treatment options and role of denosumab

Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2 1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA Abstract: Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skelet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singh AS, Chawla NS, Chawla SP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/63d3a940dabe42b59981387a6eea2a4f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63d3a940dabe42b59981387a6eea2a4f
record_format	dspace
spelling	oai:doaj.org-article:63d3a940dabe42b59981387a6eea2a4f2021-12-02T02:39:22ZGiant-cell tumor of bone: treatment options and role of denosumab1177-5491https://doaj.org/article/63d3a940dabe42b59981387a6eea2a4f2015-07-01T00:00:00Zhttp://www.dovepress.com/giant-cell-tumor-of-bone-treatment-options-and-role-of-denosumab-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2 1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA Abstract: Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-κB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid. Keywords: denosumab, giant-cell tumor of bone, sarcoma, targeted therapy, RANKL Singh ASChawla NSChawla SPDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 69-74 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Singh AS Chawla NS Chawla SP Giant-cell tumor of bone: treatment options and role of denosumab
description	Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2 1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA Abstract: Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-κB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid. Keywords: denosumab, giant-cell tumor of bone, sarcoma, targeted therapy, RANKL
format	article
author	Singh AS Chawla NS Chawla SP
author_facet	Singh AS Chawla NS Chawla SP
author_sort	Singh AS
title	Giant-cell tumor of bone: treatment options and role of denosumab
title_short	Giant-cell tumor of bone: treatment options and role of denosumab
title_full	Giant-cell tumor of bone: treatment options and role of denosumab
title_fullStr	Giant-cell tumor of bone: treatment options and role of denosumab
title_full_unstemmed	Giant-cell tumor of bone: treatment options and role of denosumab
title_sort	giant-cell tumor of bone: treatment options and role of denosumab
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/63d3a940dabe42b59981387a6eea2a4f
work_keys_str_mv	AT singhas giantcelltumorofbonetreatmentoptionsandroleofdenosumab AT chawlans giantcelltumorofbonetreatmentoptionsandroleofdenosumab AT chawlasp giantcelltumorofbonetreatmentoptionsandroleofdenosumab
_version_	1718402289233821696

Giant-cell tumor of bone: treatment options and role of denosumab

Ejemplares similares